Condition
Mesothelioma, Malignant
Estimated Enrollment: 22
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: ONC-2014-002
Study First Received: November 19, 2014
Last Updated: February 9, 2017
Estimated Primary Completion Date: December 2015
Primary Outcome Measures:
anti-tumor activity of Imatinib mesylate in combination with Gemcitabine|anti-tumor activity of Imatinib mesylate in combination with Gemcitabine in terms of Response Evaluation Criteria In Solid Tumors (RECIST) criteria|anti-tumor activity of Imatinib mesylate in combination with Gemcitabine in terms of overall survival (OS).|safety profile of the combination according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3|molecular profile of patients
Sponsors and Collaborators:
Istituto Clinico Humanitas
Website Link: https://ClinicalTrials.gov/show/NCT02303899
